National guidelines for atypical-antipsychotic use developed earlier this year by the Department of Veterans Affairs Pharmacy Benefits Management, Medical Advisory Panel, and Mental Health Strategic Healthcare Group suggested a treatment protocol for veterans that mandated two failed trials on risperidone and quetiapine before a different, and possibly more expensive, atypical antipsychotic medication could be prescribed. The new directives liberate physicians from having to consider cost before prescribing medication to patients with schizophrenia.